Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC)

Daniel Wilhelm Mueller; Gabriele Margareta Siegler; Enrico de Toni; Udo Lindig; Jurgen Siebler; Martin Walker; Salah-Eddin Al-Batran; Arndt Vogel

Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC)

Daniel Wilhelm Mueller, Gabriele Margareta Siegler, Enrico de Toni, Udo Lindig, Jurgen Siebler, Martin Walker, Salah-Eddin Al-Batran, Arndt Vogel

Department of Internal Medicine V, Division of Oncology and Hematology

Research output: Contribution to journal › Original Article › peer-review

2 Citations (Web of Science)

Original language	Undefined/Unknown
Journal	Journal of Clinical Oncology
Publication status	Published - 2020

Cite this

Mueller, D. W., Siegler, G. M., de Toni, E., Lindig, U., Siebler, J., Walker, M., Al-Batran, S.-E., & Vogel, A. (2020). Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology.

Mueller, Daniel Wilhelm ; Siegler, Gabriele Margareta ; de Toni, Enrico et al. / Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). In: Journal of Clinical Oncology. 2020.

@article{fd6bed044e63406dbfc1726fe27619db,

title = "Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC)",

author = "Mueller, {Daniel Wilhelm} and Siegler, {Gabriele Margareta} and {de Toni}, Enrico and Udo Lindig and Jurgen Siebler and Martin Walker and Salah-Eddin Al-Batran and Arndt Vogel",

year = "2020",

language = "Undefined/Unknown",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "Lippincott Williams & Wilkins ",

}

Mueller, DW, Siegler, GM, de Toni, E, Lindig, U, Siebler, J, Walker, M, Al-Batran, S-E & Vogel, A 2020, 'Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC)', Journal of Clinical Oncology.

Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). / Mueller, Daniel Wilhelm; Siegler, Gabriele Margareta; de Toni, Enrico et al.
In: Journal of Clinical Oncology, 2020.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC)

AU - Mueller, Daniel Wilhelm

AU - Siegler, Gabriele Margareta

AU - de Toni, Enrico

AU - Lindig, Udo

AU - Siebler, Jurgen

AU - Walker, Martin

AU - Al-Batran, Salah-Eddin

AU - Vogel, Arndt

PY - 2020

Y1 - 2020

UR - https://publons.com/wos-op/publon/48635168/

M3 - Originalarbeit

SN - 0732-183X

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

ER -

Mueller DW, Siegler GM, de Toni E, Lindig U, Siebler J, Walker M et al. Safety Run-In Phase (SRP) cohorts 1 and 2 of the IMMUNIB trial (AIO-HEP-0218/ass): An open-label, single-arm phase II study evaluating safety and efficacy of immunotherapy with PD-L1/L2 inhibition (nivolumab) in combination with receptor tyrosine kinase inhibition (lenvatinib) in advanced stage hepatocellular carcinoma (HCC). Journal of Clinical Oncology. 2020.

Other files and links

Cite this